Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| AX0701 | Other Identifier | Company Internal | |
| 13598 | Other Identifier | Company Internal | |
| 13855 | Other Identifier | Company Internal | |
| 13856 | Other Identifier | Company Internal | |
| 13857 | Other Identifier | Company Internal | |
| 14008 | Other Identifier | Company Internal | |
| 14007 | Other Identifier | Company Internal | |
| 14009 | Other Identifier | Company Internal |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The objective of this global non-interventional study is to evaluate the impact of Acute Exacerbation of Chronic Bronchitis(AECB) on the patient and the community as well as the safety and effect of a treatment with Moxifloxacin tablets in daily life clinical practice. This includes data on the course of symptom relief, speed of return to normal daily life activities as well as records on adverse events.
This study will be performed in accordance with international guidelines like EMEA (EMEA, EUDRALEX Volume 9A, Pharmacovigilance for Medicinal Products for Human Use) as well as local laws.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group 1 |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Moxifloxacin (Avelox, BAY12-8039) | Drug | Patients with acute exacerbation of chronic bronchitis for whom the physician decided to prescribe moxifloxacin |
|
| Measure | Description | Time Frame |
|---|---|---|
| Time until improvement of acute exacerbation | End of study |
| Measure | Description | Time Frame |
|---|---|---|
| Time until cure of acute exacerbation | End of study | |
| Severity of AECB according to Antonisen criteria | Baseline | |
| Impact of AECB on daily life activities |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Primary care clinic
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bayer Study Director | Bayer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Many Locations | Albania | |||||
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 23343427 | Derived | Chuchalin A, Zakharova M, Dokic D, Tokic M, Marschall HP, Petri T. Efficacy and safety of moxifloxacin in acute exacerbations of chronic bronchitis: a prospective, multicenter, observational study (AVANTI). BMC Pulm Med. 2013 Jan 23;13:5. doi: 10.1186/1471-2466-13-5. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D029481 | Bronchitis, Chronic |
| ID | Term |
|---|---|
| D001991 | Bronchitis |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
| D001982 | Bronchial Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077266 | Moxifloxacin |
| ID | Term |
|---|---|
| D024841 | Fluoroquinolones |
| D042462 | 4-Quinolones |
| D015363 | Quinolones |
| D011804 | Quinolines |
Not provided
Not provided
Not provided
Not provided
Not provided
| Baseline |
| Safety of Avelox under daily life treatment conditions | Throughout treatment |
| Many Locations |
| Bosnia and Herzegovina |
| Many Locations | Kazakhstan |
| Many Locations | Moldova |
| Many Locations | North Macedonia |
| Many Locations | Russia |
| Many Locations | Slovakia |
| Many Locations | Ukraine |
| D012140 |
| Respiratory Tract Diseases |
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |
| D029424 | Pulmonary Disease, Chronic Obstructive |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D006574 |
| Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |